^
Association details:
| Biomarker: | PD-L1 overexpression |
|---|---|
| Cancer: | Oral Cancer |
| Drug: | Lynparza (olaparib) (PARP inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
PD-L1-Mediated Immunosuppression in Oral Squamous Cell Carcinoma: Relationship With Macrophage Infiltration and Epithelial to Mesenchymal Transition Markers
Published date:
09/06/2021
Excerpt:
We also took into account the differences in the response of chemotherapy in OSCC patients, and evaluated sensitivity of two patient groups to four chemical drugs (olaparib, docetaxel, paclitaxel, and pazopanib). The IC50 value of each sample in OSCC was estimated, and significant differences were observed between groups, which revealed that PD-L1high group showed higher sensitivity to all drugs (Figures 6E–H, P < 0.001).
DOI:
10.3389/fimmu.2021.693881
